Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Solar Biotech Acquires Noblegen

July 25, 2023

Biotechnology

Solar Biotech Inc., a Norton, Virginia-based synthetic biology and bioprocessing company, has acquired Noblegen, an advanced digital biology and precision fermentation company based in Peterborough, Ontario. Noblegen will operate as Solar Biotech Canada and serve as the group's food-grade-certified biomanufacturing and R&D hub, expanding Solar Biotech's upstream/downstream capabilities and on‑the‑ground capacity in Canada.

Miltenyi Biotec Acquires lino Biotech

March 22, 2023

Biotechnology

Miltenyi Biotec has acquired 100% of lino Biotech from investors including Roche Venture Fund and Hightech-Grunderfonds. The acquisition brings lino's focal molography biosensor platform into Miltenyi's cell and gene therapy and research-tools portfolio to enhance potency assays and quality-control capabilities.

Ginkgo Bioworks to Acquire Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.

Ginkgo Bioworks Acquires Assets from Bitome

June 6, 2022

Biotechnology

Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.

Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

May 11, 2021

AI & Machine Learning

Ginkgo Bioworks agreed to a business combination with special purpose acquisition company Soaring Eagle Acquisition Corp., which would result in Ginkgo becoming a publicly listed company. The transaction is expected to close in the third quarter of 2021 and is expected to provide up to $2.5 billion of gross cash proceeds, including $775 million from a PIPE.